Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer

Gynecologic Oncology

Volumn 107, Issue 3, 2007, Pages 526-531

  Zhang, Zhen ^a   Yu, Yinhua ^b   Xu, Fengji ^b   Berchuck, Andrew ^c   van Haaften Day, Carolien ^d   Havrilesky, Laura J ^c   de Bruijn, Henk W A ^d   van der Zee, Ate G J ^e   Woolas, Robert P ^f   Jacobs, Ian J ^g   Skates, Steven ^h   Chan, Daniel W ^a   Bast Jr , Robert C ^b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d ROYAL HOSPITAL FOR WOMEN   (Australia)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^f ST MARY S HOSPITAL   (United Kingdom)

^g QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Artificial neural network; Early detection; Multivariate model; Ovarian cancer; Tumor marker

Indexed keywords

CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 72-4 ANTIGEN; COLONY STIMULATING FACTOR 1; TUMOR MARKER;

ARTICLE; ARTIFICIAL NEURAL NETWORK; BLOOD ANALYSIS; CANCER STAGING; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CANCER; OVARY DISEASE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; CA-125 ANTIGEN; CA-15-3 ANTIGEN; FEMALE; HUMANS; MACROPHAGE COLONY-STIMULATING FACTOR; NEOPLASM STAGING; NEURAL NETWORKS (COMPUTER); OVARIAN NEOPLASMS; ROC CURVE;

EID: 36349037122     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.08.009     Document Type: Article

References (24)

1. Berek J.S., Thomas G.M., and Ozols R.F. Ovarian cancer. Cancer Medicine. Edition 5 (2000) 1687-1720
2. Bourne T.H., Campbell S., Reynolds K.M., et al. Screening for early familial ovarian cancer with transvaginal ultrasonography and colour blood flow imaging. BMJ 306 6884 (1993) 1025-1029
3. van Nagell Jr. J.R., DePriest P.D., Reedy M.B., et al. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol Oncol 77 3 (2000) 350-356
4. Sato S., Yokoyama Y., Sakamoto T., Futagami M., and Saito Y. Usefulness of mass screening for ovarian carcinoma using transvaginal ultrasonography. Cancer 89 3 (2000) 582-588
5. Yin B.W., Dnistrian A., and Lloyd K.O. Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene. Int J Cancer 98 5 (2002) 737-740
6. Bast Jr. R.C., Klug T.L., St John E., et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 309 15 (1983) 883-887
7. Bast Jr. R.C., Siegal F.P., Runowicz C., et al. Elevation of serum CA 125 prior to diagnosis of an epithelial ovarian carcinoma. Gynecol Oncol 22 1 (1985) 115-120
8. Zurawski Jr. V.R., Knapp R.C., Einhorn N., et al. An initial analysis of preoperative serum CA 125 levels in patients with early stage ovarian carcinoma. Gynecol Oncol 30 1 (1988) 7-14
9. Einhorn N., Bast Jr. R.C., Knapp R.C., Tjernberg B., and Zurawski Jr. V.R. Preoperative evaluation of serum CA 125 levels in patients with primary epithelial ovarian cancer. Obstet Gynecol 67 3 (1986) 414-416
10. Jacobs I., and Bast Jr. R.C. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod 4 1 (1989) 1-12
11. Woolas R.P., Xu F.J., Jacobs I.J., et al. Elevation of multiple serum markers in patients with stage I ovarian cancer. J Natl Cancer Inst 85 21 (1993) 1748-1751
12. van Haaften-Day C., Shen Y., Xu F., et al. OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal. Cancer 92 11 (2001) 2837-2844
13. Jacobs I.J., Skates S.J., MacDonald N., et al. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 353 9160 (1999) 1207-1210
14. Bast Jr. R.C., Urban N., Shridhar V., et al. Early detection of ovarian cancer: promise and reality. Cancer Treat Res 107 (2002) 61-97
15. Woolas R.P., Conaway M.R., Xu F., et al. Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecol Oncol 59 1 (1995) 111-116
16. Skates S.J., Xu F.J., Yu Y.H., et al. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer 76 10 Suppl (1995) 2004-2010
17. Rosenthal A.N., and Jacobs I.J. The role of CA 125 in screening for ovarian cancer. Int J Biol Markers 13 4 (1998) 216-220
18. Baxt W.G., and Skora J. Prospective validation of artificial neural network trained to identify acute myocardial infarction. Lancet 347 8993 (1996) 12-15
19. Bottaci L., Drew P.J., Hartley J.E., et al. Artificial neural networks applied to outcome prediction for colorectal cancer patients in separate institutions. Lancet 350 9076 (1997) 469-472
20. Muzzonigro G., and Galosi A.B. Biological selection criteria for radical prostatectomy. Ann N Y Acad Sci 963 (2002) 204-212
21. Zhang Z., Barnhill S.D., Zhang H., et al. Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses. Gynecol Oncol 73 1 (1999) 56-61
22. Xu F.J., Ramakrishnan S., Daly L., et al. Increased serum levels of macrophage colony-stimulating factor in ovarian cancer. Am J Obstet Gynecol 165 5 Pt 1 (1991) 1356-1362
23. Bishop C.M. Neural Networks for Pattern Recognition (1995), Oxford University Press, Oxford
24. Jacobs I.J., Skates S., Davies A.P., et al. Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study. BMJ 313 7069 (1996) 1355-1358